On October 13, Johnson & Johnson fell 3.31% in Pre-Market Trading, trading at $255.9 per share, with turnover of $7.1785 million.
The move followed its latest quarterly report and management commentary on portfolio restructuring. Third-quarter sales were $25.4 billion, broadly in line with expectations, while adjusted EPS of $2.59 beat consensus estimates. The company also raised full-year sales guidance to $101.0 billion-$101.4 billion and adjusted EPS guidance to $11.05-$11.15.
Despite the earnings beat and higher outlook, management said it prefers to separate the hips and knees orthopaedics business rather than sell it, with the CFO indicating a target completion around mid-2027. The sharper pre-market decline suggests investors are weighing the implications of the MedTech portfolio reshaping and its effect on future growth mix and valuation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)